NCT00641238

Brief Summary

We are collecting clinical notes and results of imaging studies (CT and PET scans) from referring physicians who follow the clinical status of patients treated with radiofrequency ablation (RFA). The research objective is to determine whether the patients with (RFA) remain alive, and whether they are in remission or have progressive/ recurrent malignancy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2004

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2004

Completed
4 years until next milestone

First Submitted

Initial submission to the registry

March 17, 2008

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 24, 2008

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
Last Updated

December 15, 2023

Status Verified

December 1, 2023

Enrollment Period

6.9 years

First QC Date

March 17, 2008

Last Update Submit

December 14, 2023

Conditions

Non-small Cell Lung Cancer (NSCLC)

Keywords

NSCLClung cancer

Outcome Measures

Primary Outcomes (1)

  • Overall Survival

    5 years after diagnosis of NSCLC

Study Arms (1)

Early stage NSCLC

Early stage non-small cell lung cancer

Device: Radiofrequency ablation

Interventions

Radiofrequency ablationDEVICE

Radiofrequency ablation

Early stage NSCLC

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with clinical stage I NSCLC that are treated with Radiofrequency ablation.

You may qualify if:

  • Patients with lung masses
  • Patients who consent to radiofrequency ablation of mass

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Upstate Medical University

Syracuse, New York, 13201, United States

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungLung Neoplasms

Interventions

Radiofrequency Ablation

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Radiofrequency TherapyTherapeuticsAblation TechniquesSurgical Procedures, Operative

Study Officials

  • Ernest Scalzetti, MD

    State University of New York - Upstate Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 17, 2008

First Posted

March 24, 2008

Study Start

March 1, 2004

Primary Completion

February 1, 2011

Study Completion

February 1, 2011

Last Updated

December 15, 2023

Record last verified: 2023-12

Locations

US(1)